{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:11:02Z","timestamp":1786997462147,"version":"build-2736575974"},"reference-count":82,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"am","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.therap.2022.10.006","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T11:07:13Z","timestamp":1665140833000},"page":"157-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Addictovigilance in women, the hidden part of the iceberg?"],"prefix":"10.1016","volume":"78","author":[{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2022.10.006_bib0415","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1080\/15563650.2021.1884693","article-title":"Variation of drugs involved in acute drug toxicity presentations based on age and sex: an epidemiological approach based on European emergency departments","volume":"59","author":"Mir\u00f3","year":"2021","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.therap.2022.10.006_bib0420","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2019.01.017","article-title":"Research on women with substance use disorders: Reviewing progress and developing a research and implementation roadmap","volume":"197","author":"Meyer","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2022.10.006_bib0425","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ajem.2015.06.068","article-title":"Sex and age differences in ED patients with mental and behavioral disorders due to psychoactive substance use","volume":"33","author":"Le Querrec","year":"2015","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.therap.2022.10.006_bib0430","doi-asserted-by":"crossref","DOI":"10.1111\/fcp.12815","article-title":"Ten-year trends in hospitalizations related to cocaine abuse in France","author":"Eiden","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0435","series-title":"European drug report 2022: trends and developments","author":"European Monitoring Centre for Drugs and Drug Addiction, EMCDDA EMCfDaDA","year":"2022"},{"key":"10.1016\/j.therap.2022.10.006_bib0440","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/eurpub\/ckz064","article-title":"Trends in substance use and in the attributable burden of disease and mortality in the WHO European Region, 2010-16","volume":"29","author":"Rehm","year":"2019","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.therap.2022.10.006_bib0445","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.therap.2019.11.002","article-title":"French trends in the misuse of Fentanyl: From 2010 to 2015","volume":"75","author":"Tournebize","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.10.006_bib0450","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1111\/bcp.15323","article-title":"Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data","volume":"88","author":"Roussin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0455","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40264-021-01124-5","article-title":"A 13-year national monitoring study to assess narcotic prescriptions and indications (2007-2019)","volume":"45","author":"Perri-Plande","year":"2022","journal-title":"Drug Safe"},{"key":"10.1016\/j.therap.2022.10.006_bib0460","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1111\/bcp.15164","article-title":"Opioid misuse in community pharmacy patients with chronic non-cancer pain","volume":"88","author":"Philip","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0465","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/fcp.12346","article-title":"Impact of pregnancy on psychoactive substance use among women with substance use disorders recruited in addiction specialized care centers in France","volume":"32","author":"Pochard","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0470","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/106002809703100706","article-title":"Abuse of prescription medicines in southwestern France","volume":"31","author":"Baumevieille","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.therap.2022.10.006_bib0475","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s002280050246","article-title":"Falsified or forged medical prescriptions as an indicator of pharmacodependence: a pilot study. Community pharmacists of the Midi-Pyrenees","volume":"52","author":"Lapeyre-Mestre","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0480","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00002018-200730030-00007","article-title":"Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey","volume":"30","author":"Boeuf","year":"2007","journal-title":"Drug Safe"},{"key":"10.1016\/j.therap.2022.10.006_bib0485","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000356812","article-title":"A European community pharmacy-based survey to investigate patterns of prescription fraud through identification of falsified prescriptions","volume":"20","author":"Lapeyre-Mestre","year":"2014","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2022.10.006_bib0490","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/fcp.12356","article-title":"Medical prescriptions falsified by the patients: a 12-year national monitoring to assess prescription drug diversion","volume":"32","author":"Jouanjus","year":"2018","journal-title":"Fund Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0495","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1472-8206.2011.00950.x","article-title":"Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM survey","volume":"26","author":"Frauger","year":"2012","journal-title":"Fund Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0500","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/pds.2263","article-title":"Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey","volume":"21","author":"Nordmann","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2022.10.006_bib0505","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/fcp.12024","article-title":"OPPIDUM surveillance program: 20 years of information on drug abuse in France","volume":"27","author":"Frauger","year":"2013","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0510","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.therap.2019.09.005","article-title":"Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health","volume":"74","author":"Micallef","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.10.006_bib0515","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.therap.2018.09.056","article-title":"D\u00e9c\u00e8s en relation avec l\u2019abus de m\u00e9dicaments et substances (DRAMES) et nouveaux produits de synth\u00e8se (NPS): combien de cas depuis 5\u00a0ans?","volume":"73","author":"Sam-La\u00ef","year":"2018","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.10.006_bib0520","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.therap.2018.09.070","article-title":"Improve the benefit\/risk balance of methadone by respecting its pharmacological specificities","volume":"74","author":"Frauger","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.10.006_bib0525","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2515\/therapie\/2015009","article-title":"Signal identification in addictovigilance: the functioning of the French system","volume":"70","author":"Jouanjus","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.10.006_bib0530","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40264-016-0497-7","article-title":"Comment on: \u201cSocial media mining for toxicovigilance: automatic monitoring of prescription medication abuse from Twitter\u201d","volume":"40","author":"Jouanjus","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2022.10.006_bib0535","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.drugalcdep.2003.08.005","article-title":"Opiate maintenance with buprenorphine in ambulatory care: a 24-week follow-up study of new users","volume":"72","author":"Lapeyre-Mestre","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2022.10.006_bib0540","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1370\/afm.2098","article-title":"Mortality associated with time in and out of buprenorphine treatment in french office-based general practice: a 7-year cohort study","volume":"15","author":"Dupouy","year":"2017","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.therap.2022.10.006_bib0545","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000506630","article-title":"Primary care of opioid use disorder: the end of \u201cthe French model\u201d?","volume":"26","author":"Dupouy","year":"2020","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2022.10.006_bib0550","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/fcp.12210","article-title":"Evidence of slow-release morphine sulfate abuse and diversion: epidemiological approaches in a French administrative area","volume":"30","author":"Peyriere","year":"2016","journal-title":"Fund Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0555","doi-asserted-by":"crossref","first-page":"e000638","DOI":"10.1161\/JAHA.113.000638","article-title":"Cannabis use: signal of increasing risk of serious cardiovascular disorders","volume":"3","author":"Jouanjus","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.therap.2022.10.006_bib0560","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1111\/bcp.14812","article-title":"Adverse events of recreational cannabis use reported to the French addictovigilance network (2012-2017)","volume":"87","author":"Bouquet","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0565","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.encep.2015.09.002","article-title":"Cathinones use in Paris","volume":"42","author":"Batisse","year":"2016","journal-title":"Encephale"},{"key":"10.1016\/j.therap.2022.10.006_bib0570","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neuro.2020.03.015","article-title":"Use of new psychoactive substances to mimic prescription drugs: the trend in France","volume":"79","author":"Batisse","year":"2020","journal-title":"Neurotoxicology."},{"key":"10.1016\/j.therap.2022.10.006_bib0575","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.therap.2020.07.005","article-title":"Use of synthetic substances in France and in Europe","volume":"76","author":"Debruyne","year":"2021","journal-title":"Therapie."},{"key":"10.1016\/j.therap.2022.10.006_bib0580","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2165\/11531570-000000000-00000","article-title":"Assessment of abuse potential of benzodiazepines from a prescription database using \u2018doctor shopping\u2019 as an indicator","volume":"24","author":"Pradel","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.therap.2022.10.006_bib0585","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1472-8206.2010.00882.x","article-title":"Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network","volume":"25","author":"Frauger","year":"2011","journal-title":"Fund Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0590","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drugalcdep.2012.03.009","article-title":"Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France","volume":"126","author":"Pauly","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2022.10.006_bib0595","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"5","author":"Bihan","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.10.006_bib0600","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.therap.2019.12.006","article-title":"Community pharmacists, students in pharmacy, and requests of codeine-based medicines: observational study","volume":"75","author":"Baumevieille","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.10.006_bib0605","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.therap.2020.07.003","article-title":"Substance use among young people: from medicine to illicit substances","volume":"76","author":"Lapeyre-Mestre","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.10.006_bib0610","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/pds.4624","article-title":"Detecting the diverted use of psychoactive drugs by adolescents and young adults: a pilot study","volume":"27","author":"Jouanjus","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2022.10.006_bib0615","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/bcp.15052","article-title":"Medical prescription forms of opioid cough suppressants falsified by the patients before and after they switched from OTC to prescription-only in France","volume":"88","author":"Jouanjus","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0620","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.3390\/ijerph18157818","article-title":"Evaluation of medicine abuse trends in community pharmacies: the Medicine Abuse Observatory (MAO) in a Region of Southern Europe","volume":"18","author":"Perell\u00f3","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.therap.2022.10.006_bib0625","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/bcp.13892","article-title":"Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France","volume":"85","author":"Driot","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0630","doi-asserted-by":"crossref","first-page":"639780","DOI":"10.3389\/fpsyt.2021.639780","article-title":"Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance","volume":"12","author":"Tambon","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2022.10.006_bib0635","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.therap.2016.04.006","article-title":"Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history","volume":"71","author":"Driot","year":"2016","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.10.006_bib0640","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.therap.2020.06.006","article-title":"Addictovigilance contribution during COVID-19 epidemic and lockdown in France","volume":"75","author":"Lapeyre-Mestre","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.10.006_bib0645","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1472-8206.2010.00906.x","article-title":"Assessment of abuse of tianeptine from a reimbursement database using \u2018doctor-shopping\u2019 as an indicator","volume":"26","author":"Rouby","year":"2012","journal-title":"Fund Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0650","first-page":"89","article-title":"Doctor shopping reveals geographical variations in opioid abuse","volume":"16","author":"Nordmann","year":"2013","journal-title":"Pain Physician"},{"key":"10.1016\/j.therap.2022.10.006_bib0655","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.drugalcdep.2018.01.036","article-title":"Doctor shopping of opioid analgesics relative to benzodiazepines: a pharmacoepidemiological study among 11.7 million inhabitants in the French countries","volume":"187","author":"Ponte","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2022.10.006_bib0660","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.therap.2018.09.078","article-title":"Interest of large electronic health care databases in addictovigilance: lessons from 15 years of pharmacoepidemiological contribution","volume":"74","author":"Dupui","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.10.006_bib0665","doi-asserted-by":"crossref","first-page":"640120","DOI":"10.3389\/fpsyt.2021.640120","article-title":"Early detection of prescription drug abuse using doctor shopping monitoring from claims databases: illustration from the experience of the French Addictovigilance Network","volume":"12","author":"Soeiro","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.therap.2022.10.006_bib0670","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/fcp.12612","article-title":"Doctor shopping for methylphenidate as a proxy for misuse and potential abuse in the 67 million inhabitants in France","volume":"35","author":"Soeiro","year":"2021","journal-title":"Fund Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0675","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/j.pain.0000000000002093","article-title":"Evolution of doctor shopping for oxycodone in the 67 million inhabitants in France as a proxy for potential misuse or abuse","volume":"162","author":"Soeiro","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.therap.2022.10.006_bib0680","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.neuroscience.2018.10.002","article-title":"Sex differences in the rat hippocampal opioid system after oxycodone conditioned place preference","volume":"393","author":"Ryan","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.therap.2022.10.006_bib0685","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bcp.14415","article-title":"Ten-year trend of opioid and nonopioid analgesic use in the French adult population","volume":"87","author":"Daveluy","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0690","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/08897077.2019.1573210","article-title":"Nitrous oxide: What do we know about its use disorder potential? Results of the French Monitoring Centre for Addiction network survey and literature review","volume":"40","author":"Fidalgo","year":"2019","journal-title":"Subst Abus"},{"key":"10.1016\/j.therap.2022.10.006_bib0695","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.therap.2020.01.002","article-title":"Warning on increased serious health complications related to non-medical use of nitrous oxide","volume":"76","author":"Micallef","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.10.006_bib0700","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/ene.15370","article-title":"Myeloneuropathy induced by recreational nitrous oxide use with variable exposure levels","volume":"29","author":"Largeau","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.therap.2022.10.006_bib0705","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.neurol.2019.10.005","article-title":"Another extensive nitrous oxide (N2O) myelopathy: The wood for the trees?","volume":"176","author":"Demas","year":"2020","journal-title":"Rev Neurol"},{"key":"10.1016\/j.therap.2022.10.006_bib0710","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/fcp.12771","article-title":"Psychoactive substance use among students: A cross-sectional analysis","volume":"36","author":"Perino","year":"2022","journal-title":"Fund Clin Pharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0715","doi-asserted-by":"crossref","first-page":"112894","DOI":"10.1016\/j.fct.2022.112894","article-title":"Nitrous oxide abuse in the emergency practice, and Review of toxicity mechanisms and potential markers","volume":"162","author":"Joncquel Chevalier-Curt","year":"2022","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.therap.2022.10.006_bib0720","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.3390\/ijerph19095237","article-title":"Recreational nitrous oxide use and associated factors among health profession students in France","volume":"19","author":"Inquimbert","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.therap.2022.10.006_bib0725","first-page":"304","article-title":"Is nitrous oxide really that joyful?","volume":"75","author":"Glijn","year":"2017","journal-title":"Neth J Med"},{"key":"10.1016\/j.therap.2022.10.006_bib0730","first-page":"D2044","article-title":"Nitrous oxide-induced polyneuropathy","volume":"161","author":"Conjaerts","year":"2017","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.therap.2022.10.006_bib0735","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12883-017-0990-3","article-title":"Nitrous oxide induced subacute combined degeneration with longitudinally extensive myelopathy with inverted V-sign on spinal MRI: a case report and literature review","volume":"17","author":"Yuan","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1016\/j.therap.2022.10.006_bib0740","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp-2017-317768","article-title":"Recreational nitrous oxide-associated neurotoxicity","volume":"89","author":"Johnson","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.therap.2022.10.006_bib0745","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1017\/cjn.2018.15","article-title":"Subacute combined degeneration from nitrous oxide abuse in a patient with pernicious anemia","volume":"45","author":"Anderson","year":"2018","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.therap.2022.10.006_bib0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajem.2018.05.029","article-title":"Vitamin B12 deficiency-induced neuropathy secondary to prolonged recreational use of nitrous oxide","volume":"36","author":"Egan","year":"2018","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.therap.2022.10.006_bib0755","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00415-018-8801-3","article-title":"No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation","volume":"265","author":"Keddie","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.therap.2022.10.006_bib0760","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4103\/0028-3886.237029","article-title":"Glucocorticoid treatment of myeloneuropathy induced by nitrous oxide toxicity","volume":"66","author":"Ji","year":"2018","journal-title":"Neurol India"},{"key":"10.1016\/j.therap.2022.10.006_bib0765","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/thoraxjnl-2017-210291","article-title":"Pneumomediastinum and pneumorrhachis from recreational nitrous oxide inhalation: no laughing matter","volume":"73","author":"Tavare","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.therap.2022.10.006_bib0770","doi-asserted-by":"crossref","first-page":"l1923","DOI":"10.1136\/bmj.l1923","article-title":"Subacute progressive sensorimotor symptoms","volume":"365","author":"Francis","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.therap.2022.10.006_bib0775","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.braindev.2018.12.003","article-title":"Recreational nitrous oxide abuse related subacute combined degeneration of the spinal cord in adolescents - A case series and literature review","volume":"41","author":"Lan","year":"2019","journal-title":"Brain Dev"},{"issue":"2","key":"10.1016\/j.therap.2022.10.006_bib0780","doi-asserted-by":"crossref","first-page":"e228001","DOI":"10.1136\/bcr-2018-228001","article-title":"One month of nitrous oxide abuse causing acute vitamin B 12 deficiency with severe neuropsychiatric symptoms","volume":"12","author":"Lundin","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.therap.2022.10.006_bib0785","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-022-02673-x","article-title":"Thromboembolic complications of recreational nitrous oxide (ab)use: a systematic review","author":"Oulkadi","year":"2022","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.therap.2022.10.006_bib0790","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/02698811221077194","article-title":"Nitrous oxide-induced reproductive risks: Should recreational nitrous oxide users worry?","volume":"36","author":"van Amsterdam","year":"2022","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.therap.2022.10.006_bib0795","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2515\/therapie\/2014221","article-title":"Evaluation of abuse and dependence in addiction monitoring systems: tramadol as an example","volume":"70","author":"Roussin","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.10.006_bib0800","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ejp.1901","article-title":"Perceived risk of opioid use disorder secondary to opioid analgesic medication use by the general population in France","volume":"26","author":"Lavergne","year":"2022","journal-title":"Eur J Pain"},{"key":"10.1016\/j.therap.2022.10.006_bib0805","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/15563650.2022.2060116","article-title":"Differences in clinical features associated with cannabis intoxication in presentations to European emergency departments according to patient age and sex","author":"Schmid","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.therap.2022.10.006_bib0810","doi-asserted-by":"crossref","first-page":"173107","DOI":"10.1016\/j.pbb.2021.173107","article-title":"Sex differences and the endocannabinoid system in pain","volume":"202","author":"Blanton","year":"2021","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.therap.2022.10.006_bib0815","first-page":"305","volume":"237","author":"Matheson","year":"2020","journal-title":"Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults. Psychopharmacology (Berl)"},{"key":"10.1016\/j.therap.2022.10.006_bib0820","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.therap.2020.06.017","article-title":"The cardiovascular health of prisoners who use cannabis: an exploratory study among hospitalised prisoners","volume":"75","author":"Mongiatti","year":"2020","journal-title":"Therapie"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722001755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722001755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:23Z","timestamp":1758567323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595722001755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0040595722001755"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2022.10.006","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addictovigilance in women, the hidden part of the iceberg?","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2022.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}